View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 7, 2022

Revolo obtains MHRA approval for Phase II autoimmune disease drug trials

One of the trials will enrol moderate-to-severe active rheumatoid arthritis patients.

Revolo Biotherapeutics has secured the approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate two Phase II trials of its autoimmune disease drug candidate ‘1805.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The immune-resetting drug is an analogue of the endogenous immune-regulatory binding immunoglobulin protein (BiP).

BiP plays a crucial role in immune function that readjusts the immune system for durable disease remission. 

One of the trials will enrol moderate-to-severe active rheumatoid arthritis (RA) patients while another Phase II trial will have individuals with non-infectious, active, intermediate, or posterior uveitis or panuveitis.

A randomised, placebo-controlled, double-blind, dose-escalation Phase II trial will analyse the impact of ‘1805 in 92 RA patients.

Set to have a treatment period as well as a follow-up period of 24 weeks, the trial will assess the efficacy of 15mg, 50mg, or 100mg intravenous (IV) doses of the drug.

Another open-label, prospective, 16-week, dose-escalation Phase II trial will analyse the efficacy and safety of ‘1805 in non-infectious, active, intermediate, or posterior uveitis or panuveitis patients. 

It plans to have 25 subjects to analyse 15mg, 50mg, or 100mg IV doses of the drug.

Clinical response as assessed at week 12 will be the primary efficacy endpoint of this trial.

According to findings from a prior Phase IIa trial for severe RA, the drug was found to be potentially safe. 

It enrolled 24 individuals with severe RA who do not respond to standard of care therapy. 

Revolo Bio CEO Jonathan Rigby said: “Given ‘1805’s mechanism of action that resets the immune system upstream of the inflammatory cascade, versus after inflammation has occurred, we believe this molecule has the potential to truly change the treatment landscape for multiple autoimmune diseases. 

“We look forward to building on the promising clinical profile from our first Phase IIa trial of ‘1805 in patients with RA and continue to show its clinical potential in other autoimmune diseases with high unmet needs, such as Uveitis, the leading cause of adult blindness in western countries.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena